Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

  • This patent protects the use of glenzocimab in thrombotic diseases until 2036
  • This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan

Press Release: